Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066 ↗

Phase 2 Active not recruiting 33 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

Timeline

Start: 2023-02-13
Primary completion: 2028-02-14
Completion: 2028-02-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASTX727	Unknown	20 mg/m2	Oral
Subject	Azacitidine	Other / unclassified	75 mg/m2	Subcutaneous
Subject	Decitabine	Small molecule	20 mg/m2	Intravenous
Subject	Sabatolimab	Monoclonal antibody	200 mg	Intravenous
Subject	Sabatolimab	Monoclonal antibody	400 mg	Intravenous
Subject	Sabatolimab	Monoclonal antibody	800 mg	Intravenous
Subject	Spartalizumab	Monoclonal antibody	100 mg	Intravenous
Subject	Venetoclax	Small molecule	400 mg	Oral

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Summary

Timeline

Drugs

Indications